Tag Archives: Epirus Biopharmaceuticals

July, 2015

  • 15 July

    Epirus Enters Biosimilars Collaboration with Polpharma Group

    BOSTON, July 14, 2015 (GLOBE NEWSWIRE) —  EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS) and Polpharma Group today announced the signing of a multi-product, multi-region profit-sharing collaboration for select EPIRUS biosimilars, including BOW015 (infliximab, reference biologic Remicade®), BOW050 (adalimumab, reference biologic Humira®) andBOW070 (tocilizumab, reference biologic Actemra®), representing $6 billion in innovator sales in …